Abeona Therapeutics Inc. — FY2019 Form 10-K
Reporting period: Year ended December 31, 2019; filed March 16, 2020. Abeona is a clinical-stage biopharmaceutical company developing gene and cell therapies for rare genetic diseases. It had no approved product generating material sales.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0 | $3.0 million |
| Research and development expense | $48.6 million | $38.7 million |
| General and administrative expense | $20.7 million | $20.1 million |
| Depreciation and amortization | $7.8 million | $2.4 million |
| Loss from operations | $77.1 million | $58.2 million |
| Net loss | $76.3 million | $56.7 million |
| Basic and diluted loss per share | $1.51 | $1.19 |
| Cash and cash equivalents | $129.3 million | $18.8 million |
| Working capital | $93.7 million | $68.5 million |
| Total liabilities | $45.0 million | $40.4 million |
Operating cash outflow was $62.8 million in 2019, versus $39.1 million in 2018; capital expenditures were $6.3 million. Financing provided $113.9 million net, principally from a December public offering and sales under the Jefferies equity program. No material product revenue or profit was reported, so operating margins are not meaningful. The filing does not report conventional funded debt; liabilities include lease obligations and amounts payable to a licensor.
Material changes versus 2018
- Revenue fell to zero from $3.0 million, as foundation revenue and MuGard royalties were both zero in 2019. Foundation grants received cumulatively were $5.7 million, but revenue recognition tracks eligible program costs.
- Net loss widened by $19.6 million. R&D rose $9.9 million, primarily from increased clinical and development activity and staffing; depreciation and amortization rose $5.4 million, largely reflecting the REGENXBIO license and Cleveland facility investment.
- Cash and working capital increased following substantial equity fundraising, partly offset by operating cash use, capital spending and licensor obligations. Shares outstanding increased from 47.9 million at year-end 2018 to 83.6 million at year-end 2019; the offering also included 9.0 million pre-funded warrants.
Outlook, programs, risks and unusual items
- Management estimated existing cash would fund operations through the second quarter of 2021 under its current operating plan, while stating that additional financing would be needed for planned development. The company had an accumulated deficit of $486.5 million and expected continued losses.
- EB-101: FDA removed a clinical hold in December 2019 after requesting additional transport-stability data. The company initiated the pivotal Phase III VIITAL study in the first quarter of 2020, targeting 10–15 patients. Enrollment, manufacturing and study design remain risks.
- ABO-102 for MPS IIIA: 14 patients had been treated by November 2019; management reported biomarker and liver-volume reductions and encouraging neurocognitive signals in younger patients, with no treatment-related serious adverse events reported to date. ABO-101 for MPS IIIB had treated seven patients, with reported biomarker signals and no serious drug-related adverse events to date. These are interim clinical observations, not proof of efficacy.
- Other candidates included early-stage programs for CLN1, CLN3, cystic fibrosis and retinal disease, alongside the AIM capsid platform. The company’s Cleveland cGMP facility build-out continued; commercial-scale AAV capacity remained a future phase.
- REGENXBIO license obligations are significant: $28 million was due within one year at December 31, 2019, including an $8 million amended payment due April 1, 2020 and a guaranteed $20 million payment due November 4, 2020. Further annual fees, potential milestones and royalties may apply.
- The filing identified risks from clinical and regulatory uncertainty, rare-disease patient recruitment, manufacturing and supply reliability, dependence on partners and licensed intellectual property, future financing and dilution, reimbursement, competition, and the coronavirus outbreak’s potential disruption to trials, suppliers and operations.
- A putative securities class action filed in November 2019 was voluntarily dismissed by the plaintiff in January 2020. A 2019 arbitration ruling resulted in the return of 450,000 shares and a $0.3 million non-cash expense.
- Subsequent leadership changes were disclosed: the President and Chief Scientific Officer resigned effective January 10, 2020; the CFO and Executive Chairman were expected to depart effective March 31, 2020. The CFO agreed to provide transition support through June 30, 2020.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. Management reported disclosure controls and internal control over financial reporting as effective at year-end.
Important facts for investors to verify
- Whether the reported cash runway through Q2 2021 remains achievable given actual burn, clinical spending and the licensor payments.
- Progress, enrollment, endpoint requirements and manufacturing readiness for the EB-101 Phase III study, including any subsequent FDA feedback.
- Updated safety and efficacy evidence from ABO-102 and ABO-101 trials, including durability and outcomes beyond biomarkers.
- Current share count, pre-funded warrant status, and potential dilution from future equity financing or the Jefferies sales program.
- Payment status and continuing terms of the REGENXBIO license, including future fixed fees, milestones and royalties.
- Whether the disclosed management transitions and coronavirus-related risks affected execution, trial timelines or operating costs.